Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis

Abstract

Systemic Lupus Erythematosus (SLE) patients experience premature atherosclerosis. A deranged lipid metabolism and use of immunosuppressive medications accounts partially for the accelerated process. The role of autoimmunity in atherosclerosis has recently been highlighted. Autoantigenic determinants thought to play a role in the development of atherosclerosis include: modified lipoproteins, heat shock proteins and β2-glycoprotein I (a target of ‘autoimmune’ anticardiolipin antibodies). In this present work we determined autoimmune markers which may be associated with premature atherosclerotic process found in SLE patients. We have found that antibodies to oxLDL were raised in the sera of lupus patients and cross-reacted with cardiolipin and with β2GPI. OxLDL containing immune-complexes of the IgG and IgM isotypes were both elevated in the SLE patients as compared with healthy controls. Patients with high Lipoprotein (a) concentrations (> 30 mg/dl) had higher levels of IgM oxLDL-containing immune-complexes. IgM but not IgG anti-HSP-65 antibodies were elevated in the lupus patients and levels of oxLDL containing immune-complexes correlated positively with the presence of anti-HSP 65 antibodies.

Lysophosphatidylcholine (LPC) is a peroxide-derivative formed during LDL oxidation, was shown to evoke a humoral response in healthy subjects. Antibodies to lysophosphatidylcholine of the IgG but not the IgM isotype were reduced in SLE patients compared with controls, suggesting it may be ‘consumed’ into oxLDL containing immune complexes.

Therefore, SLE patients exhibit a humoral autoimmune response towards the antigenic candidates incriminated in the progression of atherosclerosis. These findings may help identify factors that are involved in accelerating atherogenesis in SLE patients.

Keywords

atherosclerosis oxLDL immune complexes autoimmunity SLE

Get full access to this article

View all access options for this article.

References

Ross R . The pathogenesis of atherosclerosis: a perspective for the 1990s . Nature 1993; 362: 801–809 .

Libby P , Hansson GK . Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions . Lab Invest 1991; 64: 5–11 .

Wick G , Schett G , Auberger A et al. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27–33 .

Witztum JL . The oxidation hypothesis of atherosclerosis . Lancet 1994; 344: 793–795 .

Salonen JT , Hertualou S , Yamamoto R et al. Antibodies against oxidized LDL and the progression of carotid atherosclerosis . Lancet 1992; 339: 883–887 .

Puurunen M , Mantarr M , Manuialen V et al. Antibodies against oxidized low density lipoprotein predicting myocardial infarction . Arch Intern Med 1994; 154: 2605–2609 .

Palinski W , Miller E , Witztum JL . Immunization of low density lipoprotein (LDL) deficient rabbits with homologeous malondialde-hyde-modified LDL reduces atherogenesis . Proc Natl Acad Sci USA 1995; 92: 821–825 .

Ameli SA , Hultgardh-Nilsson, Regenstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits . Arterioscler Thromb Vasc Biol 1996; 16: 1074–1079 .

George J , Akrek A , Gilburd B et al. Hyperimmunization of apoE deficient mice with homologous MDA-low density lipoprotein suppresses early atherogenesis . Atherosclerosis 1998; 138: 147–152 .

10.

Vaarala O , Alfthau G , Jauhiainen M et al. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus . Lancet 1993; 341: 923–925 .

11.

Galli M , Comfurious MP , Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor . Lancet 1990; 335: 1544–1547 .

12.

George J , Apek A , Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies . Lupus 1997; 6: 723–729 .

13.

George J , Aprek A , Gilburd B et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with b2 glycoprotein I . Circulation 1998; 15: 1108–1115 .

14.

Quinn MT , Parthasarathy S , Steinberg D . Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis . Proc Natl Acad Sci USA 1988; 85: 2805–2809 .

15.

Schafer-Elinder L , Hedrin U , Durnitrescu A et al. Presence of different isoforms of phospholipase A2 in tissue slices from atherosclerotic carotid plaque . Arteriscler Thromb Vasc Biol 1997; 17: 2257–2263 .

16.

Wu R , Huang YH , Elinder LS , Frostegard J . Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL . Arterioscler Thromb Vasc Biol 1998; 18: 626–630 .

17.

Welch WJ . Mammalian stress response: cell physiology, structure-/function of stress proteins, and implications for medicine and disease . Physiol Rev 1992; 72: 1063–1081 .

18.

Xu Q , Willeit J , Marosa M et al. Induction of arteriosclerosis in normocholesterolemic mice rabbits by immunization with heat shock protein 65 . Arterioscler Thrombosis 1992; 12: 789–799 .

19.

Xu Q , Willeit J , Marosa M et al. Association of serum antibodies to heat shockprotein65withcarotidartherosclerosis .Lancet 1993;341: 255–259 .

20.

Schett G , Xu Q , Amberger A et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity . J Clin Invest 1995; 96: 2569–2577 .

21.

Schett G , Metzler B , Mayr M et al. Macrophage lysis mediated by autoantibodies to heat shock protein 60=65 . Artherosclerosis 1997; 128: 27–38 .

22.

Tsakraklidesm VG , Blieden IC , Edwards JE . Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus . Am Heart J 1974; 87: 637–641 .

23.

Jonsson H , Nived O , Sturfelt G . Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population . Medicine (Baltimore) 1989; 68: 141–150 .

24.

MacGregor A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus . Ann Rheum Dis 1992; 51: 152–155 .

25.

Borba EF , Santos RD , Bonfa E et al. Lipoprotein (a) levels in systemic lupus erythematosus . J Rheumatol 1994; 21: 220–223 .

26.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1279 .

27.

George J , Blank M , Hojnik M et al. Oxidized low density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome . Clin Exp Immunol 1997; 108: 227–233 .

28.

Maggi E , Bellazzi R , Gazo A et al. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis . Kidney Int 1994; 46: 869–876 .

29.

Kiener PA , Ranklin BM , Davis PM et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells . Arterioscler Thromb Vasc Biol 1995; 15: 990–999 .

30.

Virella G , Munoz JF , Galbraith GM et al. Activation of human monocyte derived macrophages by immune complexes containing low density lipoprotein . Clin Immunol Immunopathol 1995; 75: 179–189 .

31.

Gisinger C , Lopes-Virella MF . Lipoprotein immune complexes and diabetic vascular complications . Diabetes 1992; Suppl 2: 92–96 .

32.

Mironova M , Virella G , Virella-Lowell I et al. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls . Clin Immunol Immunopathol 1997; 85: 73–82 .

33.

Festa A , Kopp HP , Schernthaner G et al Autoantibodies to oxidised low density lipoprotein are inversely related to metabolic control and microvascular complications . Diabetologia 1998; 41: 350–356 .

34.

Kabakov AE , Tertov VV , Saence VA et al. The atherogenic effect of lupus sera: systemic lupus erythematosus derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta . Clin Immunol Immunopathol 1992; 63: 214–220 .

35.

N Bostom AG , Cupples LA , Jenner JL et al. Elevated plasma Lp(a) and coronary heart disease in men aged 55 years and younger<Eth>a prospective study . JAMA 1996; 276: 544–548 .

36.

Nachman RL . Thrombosis and atherogenesis-molecular connections . Blood 1992; 79: 1897–1906 .

37.

Sorensen KE , Celermajer DS , Georgakopoulos et al. Impairment of endothelium-dependent dilatation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level . J Clin Invest 1994; 93: 50–55 .

38.

Pruzanski, Gouldin N , Flower R W et al. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus correlative study with disease activity . J Rheumatol 1994; 21: 252–257 .

39.

Simantov R , LaSala JM , Lo SK et al. Activation of cultured endothelial cells by antiphospholipid antibodies . J Clin Invest 1995; 96: 2211–2219 .

40.

George J et al. Differential effects of anti-b2GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome . Circulation 1998; 97: 900–906 .

41.

Luliano L , Pratico D , FerroD etal. Enhancedlipidperoxidationinpatients positive for antiphospholipid antibodies . Blood 1997; 90: 3931–3935 .